An analgesic that fits no category
There are drugs that are easy to classify and others that resist every label. Tramadol belongs to the latter group. It appears in medical reference books alongside codeine and morphine in the opioid family, but its mode of action is as much antidepressant as it is classic analgesic. This ambiguity is precisely what should be understood before discussing it, as both its medical utility and its frequently underestimated risks stem from it.
In Spain, it is a widely prescribed medication for moderate to severe pain, and for years, there has also been off-label, recreational, or self-medication use that has grown in various countries. For this reason, it is worth looking at it closely: not as just any opioid, but as a molecule with several simultaneous mechanisms and a narrower safety margin than its image as a “mild” drug suggests.
From Grünenthal to the global market
The molecule was synthesized by the German laboratory Grünenthal in 1962, as part of the search—common at the time—for an opioid analgesic that would relieve pain without causing dependence or respiratory depression, the two major drawbacks of opiates. After more than a decade of research, it reached the market in 1977. The goal was a safer opioid; what they obtained was a centrally acting analgesic that, strictly speaking, is not much of an opioid at all.
Today, the original patent has given way to dozens of brands worldwide, and tramadol is marketed in very different forms: tablets, capsules, drops, and injectable solutions, in addition to extended-release presentations and combinations with paracetamol or other peripheral analgesics. This variety of formats is not a minor detail: it changes the speed at which the active ingredient enters the body and, with it, the profile of effects and risks.
Three mechanisms in a single molecule
What makes tramadol unique is that it does not act through a single pathway, but through several at once. It is worth breaking them down, as each contributes a part of the picture:
- Weak opioid action. It is an agonist of μ-opioid receptors, but with very low affinity. To get an idea: its binding to those receptors is much lower than that of codeine—already a weak opiate—and thousands of times lower than that of morphine. A good part of the opioid effect does not come from the tramadol itself, but from a metabolite, O-desmetiltramadol, which the liver generates through the CYP2D6 enzyme. Hence, analgesia takes longer to appear than with other opioids.
- Serotonergic effect. It promotes the release of serotonin, in line with what certain empathogenic stimulants do, although to a lesser extent.
- Noradrenergic effect. It inhibits the reuptake of norepinephrine, which raises the levels of this neurotransmitter, a mechanism more characteristic of stimulants and some antidepressants.
It is no coincidence that structurally, tramadol resembles both codeine (with which it shares a metabolic pathway) and venlafaxine, an antidepressant that inhibits the reuptake of serotonin and norepinephrine. Added to this are other documented actions—NMDA antagonism, and effects on certain serotonergic, nicotinic, and muscarinic receptors—that make its pharmacology quite convoluted. The analgesic mechanism itself is attributed to the synergy between the weak opioid action and the modulation of serotonin and norepinephrine, rather than the isolated opioid effect. One fact illustrates this well: tramadol’s analgesia is not completely reversed by naloxone, the standard antidote for opioids.
Why the risk is where it is least looked at
The image of tramadol as a “minor” opioid creates a false sense of security. Its delicate points are not so much in the opioid aspect as in the serotonergic one and its effect on the seizure threshold.
Serotonergic interactions. Combining it with other substances that act on serotonin—SSRI antidepressants, tricyclics, MAOIs, or substances like MDMA—can lead to serotonin syndrome, a potentially serious condition. The risk is compounded because some of these drugs also slow down the metabolism of tramadol, prolonging and intensifying its effect.
Seizures. Tramadol lowers the seizure threshold, meaning it increases the likelihood of suffering epileptic-type crises. This risk is elevated when mixed with stimulants and at high doses, which is why package inserts insist on not exceeding the maximum daily dose indicated by the laboratory. It is not an anecdotal effect: it appears even in people with no history of epilepsy.
Dependence. Although it was designed with the intention of reducing the addictive potential of opioids, tramadol can generate tolerance, dependence, and withdrawal symptoms that mix opioid traits with atypical symptoms due to its serotonergic and noradrenergic components. Abrupt discontinuation after prolonged use is not trivial.
Contraindications and described adverse effects
Without going into usage guidelines, it is worth knowing what the technical data sheet itself warns. Tramadol is discouraged, among other cases, in people with hypersensitivity to the drug, uncontrolled epilepsy, renal or hepatic insufficiency, and in situations of intoxication by alcohol, hypnotics, opioids, or psychotropic drugs. It should also not be combined with medications that act on serotonin or others that lower the seizure threshold.
Among the adverse effects, the most frequent are nausea and dizziness; followed by vomiting, constipation, dry mouth, headache, and drowsiness. Less frequently, cardiovascular (palpitations, tachycardia, hypotension), neurological (tremor, paresthesia, seizures, respiratory depression), and psychiatric (confusion, anxiety, hallucinations, nightmares, and sleep disorders) alterations are described. Drowsiness and blurred vision make it inadvisable to drive or operate machinery.
Critical reading and risk reduction
The narrative of an “opioid without the problems of opioids” deserves nuance. Tramadol solved some classic drawbacks in exchange for introducing others that are less intuitive, linked precisely to what distances it from the opioid family: its action on serotonin and norepinephrine. Anyone who considers it harmless because it is “not morphine” is using the wrong framework.
Three ideas for a prudent reading:
- Individual variability is real. The effect depends largely on the CYP2D6 enzyme, whose activity varies greatly from one person to another due to genetics and interactions. This explains why the same amount produces relief in some and intense or null effects in others.
- Mixtures are the critical point. Most of the serious episodes described do not come from tramadol in isolation, but from its combination with alcohol, other depressants, stimulants, or serotonergic drugs.
- The healthcare professional is the appropriate interlocutor. Any questions about its use, discontinuation, or combination with an ongoing treatment should be directed to a doctor or pharmacist, who knows the complete clinical history.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
